The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | Efficacy of transplantation in HL
In this video, Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the efficacy of both autologous and allogeneic stem cell transplantation (SCT) in patients with Hodgkin lymphoma (HL). Prof. Nieto further highlights a study which aims to induce complete response (CR) in patients and improve curability. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
